By Sam Wong. A woman with advanced breast cancer has made a dramatic recovery after receiving a personalised therapy using her own immune cells. A year later, they had disappeared. Two and a half years on from treatment, she remains healthy. Since having the treatment, she has resumed a normal life, including long hikes and kayaking expeditions.
Triple Negative Breast Cancer: New Treatments
Breast cancer - Diagnosis and treatment - Mayo Clinic
Researchers have engineered an oncolytic virus to kill cancer cells and boost the immune response against tumors. In a new study, the virus provided T cells around tumors with a hormone they need for their own cell-killing functions. The approval also covers adults with non-small cell lung cancer harboring a ROS1 gene fusion. A new NCI-supported study showed that altering cancer cell metabolism by feeding mice a diet very low in the nutrient methionine improved the ability of chemotherapy and radiation therapy to shrink tumors. An NCI-funded clinical trial is testing the immunotherapy drug nivolumab Opdivo in people who have advanced cancer and an autoimmune disease, such as rheumatoid arthritis, lupus, or multiple sclerosis, who are often excluded from such trials.
AI reveals new breast cancer types that respond differently to treatment
Those with essentially curable cancers who refused the right treatment stand out the most. She was only 30 when she was diagnosed with breast cancer, as I learned later from her medical history. It was localized to her left breast and contained within the relatively small tumor; there were no signs it had spread to other parts of her body.
Scientists have used artificial intelligence to recognise patterns in breast cancer—and uncovered five new types of the disease each matched to different personalised treatments. Their study applied AI and machine learning to gene sequences and molecular data from breast tumours , to reveal crucial differences among cancers that had previously been lumped into one type. The new study, led by a team at The Institute of Cancer Research, London, found that two of the types were more likely to respond to immunotherapy than others, while one was more likely to relapse on tamoxifen. The researchers are now developing tests for these types of breast cancer that will be used to select patients for different drugs in clinical trials , with the aim of making personalised therapy a standard part of treatment.